Related Experiment Video
Updated: Jul 6, 2026
08:04
Culturing and Screening the Plant Parasitic Nematode Ditylenchus dipsaci
Published on: January 31, 2022
Characterization of solid-state forms of mebendazole
S Kumar1, G Chawla, M E Sobhia
1Department of Pharmaceutical Technology (Formulations), National Institute of Pharmaceutical Education and Research, Nagar, Punjab, India.
Die Pharmazie
|April 3, 2008
Summary
Researchers explored different solid-state forms of mebendazole (MBZ), an antihelmentic drug. They identified new solvates and characterized various mebendazole forms using multiple analytical techniques, revealing insights into its solid-state properties.
Area of Science:
- Pharmaceutical Sciences
- Solid-State Chemistry
Background:
- Mebendazole (MBZ) is a benzimidazole antihelmentic drug.
- Understanding its solid-state forms is crucial for drug formulation and efficacy.
Purpose of the Study:
- To generate and characterize various solid-state forms of mebendazole.
- To explore the existence of different polymorphic forms and new solvates.
- To investigate the solubility advantage of the new solvates.
Main Methods:
- Polymorphic screening using diverse solvents.
- Characterization via thermoanalytical (DSC, TGA, HSM), crystallographic (XRD), microscopic (optical, polarized), and spectroscopic (FTIR) techniques.
- Solubility studies and molecular modeling.
Main Results:
- Recrystallization yielded known forms A, B, and C from specific solvent mixtures.
- Two new mebendazole solvates were successfully generated using N,N-Dimethyl acetamide (DMA) and N,N-dimethyl formamide (DMF).
- Characterization confirmed the distinct nature of these solid-state forms.
Conclusions:
- The study successfully identified and characterized new solvates of mebendazole.
- The findings contribute to a deeper understanding of mebendazole's solid-state behavior.
- Further research into these forms may lead to improved drug formulations.
Related Concept Videos
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
01:11Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...